Literature DB >> 8977463

Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail.

F Kronenberg1, E Trenkwalder, H Dieplinger, G Utermann.   

Abstract

Prospective case-control studies investigating lipoprotein(a) [Lp(a)] as a risk factor for atherosclerosis have measured Lp(a) in samples stored frozen up to nearly 20 years. We therefore prospectively examined the influence of long-term plasma sample storage on measured values, depending on the molecular weight of apolipoprotein(a) [apo(a)] isoforms. Apo(a) phenotyping was performed in 310 plasma samples, and Lp(a) was measured after 3 and 28 months of storage at -80 degrees C. The values of both measurements correlated significantly for both low- and high-molecular-weight apo(a) phenotypes (r = .97 and r = .98, respectively, P < .001). Nevertheless, we detected on average a small decrease of 4.83% from mean +/- SD (median) 21.24 +/- 23.54 (11.10) mg/dL to 20.02 +/- 21.72 (10.55) mg/dL, which was statistically significant (P < .001). The absolute and relative Lp(a) decrease over time became larger with a decreasing number of kringle IV repeats of apo(a) (P < .05), and Lp(a) decreased markedly more in subjects with low-molecular-weight compared with those with high-molecular-weight apo(a) isoforms (-3.26 versus -0.46 mg/dL, P < .05). More than 70% of the absolute Lp(a) decrease in the total sample was caused by samples with low-molecular-weight apo(a) isoforms, which represented only 27% of the sample. Low-molecular-weight apo(a) isoforms are reportedly more frequent in patients with atherothrombotic disease compared with control subjects. Measurement of Lp(a) in several-year-old frozen samples is therefore likely to result in a preferential decrease and false lower Lp(a) concentrations in patient groups compared with control groups. The negative results of some prospective studies with retrospective measurement of Lp(a) may be caused by such an artifact.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977463     DOI: 10.1161/01.atv.16.12.1568

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  15 in total

1.  Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study.

Authors:  Mika Kivimäki; Costan G Magnussen; Markus Juonala; Mika Kähönen; Johannes Kettunen; Britt-Marie Loo; Terho Lehtimäki; Jorma Viikari; Olli T Raitakari
Journal:  Int J Epidemiol       Date:  2010-11-14       Impact factor: 7.196

Review 2.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

3.  Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; Christie M Ballantyne; Weihong Tang
Journal:  Atherosclerosis       Date:  2017-11-26       Impact factor: 5.162

Review 4.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

5.  A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes.

Authors:  I Shai; M B Schulze; J E Manson; M J Stampfer; N Rifai; F B Hu
Journal:  Diabetologia       Date:  2005-06-22       Impact factor: 10.122

6.  Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease.

Authors:  V Solfrizzi; F Panza; A D'Introno; A M Colacicco; C Capurso; A M Basile; A Capurso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

7.  Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study.

Authors:  Bernadette Boden-Albala; Douglas E Kargman; I-Feng Lin; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Cerebrovasc Dis       Date:  2010-07-23       Impact factor: 2.762

8.  Inulin-enriched pasta affects lipid profile and Lp(a) concentrations in Italian young healthy male volunteers.

Authors:  Francesco Russo; Guglielmina Chimienti; Giuseppe Riezzo; Gabriella Pepe; Giuseppe Petrosillo; Marisa Chiloiro; Emanuele Marconi
Journal:  Eur J Nutr       Date:  2008-10-13       Impact factor: 5.614

9.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

10.  Gemfibrozil treatment in patients with elevated lipoprotein a: a pilot study.

Authors:  A G Fereshetian; M Davidson; H Haber; D M Black
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.